Confo Therapeutics Is A Clinical Stage Biotechnology Company Based In Ghentbelgiumfounded In 2015It Specializes In Novel Drug Discovery Aimed At Metabolic And Endocrine Diseasesthe Company Utilizes Its Proprietary Confobodyatechnology To Stabilize Functional Conformations Of G Protein Coupled Receptorsgpcrs Which Are Crucial For Many Physiological Processesthis Innovative Approach Allows For The Discovery Of Small Molecules And Biologics Targeting Previously Challenging Drug Targets The Confobodyaplatform Employs Conformation Specific Antibodies To Lock Gpcrs Into Relevant Functional Statesfacilitating The Identification Of Various Modulatorsincluding Agonists And Antagonistsconfo Therapeutics Is Advancing A Multi Indication Pipeline Of Candidates For Metabolic And Endocrine Disorderssupported By A Recent A 60 Million Series B Financingthe Company Collaborates With Leading Pharmaceutical Partners And Is Led By Ceo Drcedric Ververkenalong With A Team Of Experts In Biopharmaceuticals And Drug Development
